🧭 Overview
SYNGAP1 disorder is a rare genetic neurodevelopmental condition caused by a mutation in the SYNGAP1 gene (Chromosome 6).
👉 This mutation leads to reduced production of an important brain protein needed for synaptic development and communication between brain cells.
It typically results in:
- 🧠 Moderate to severe intellectual disability
- 📉 Global developmental delays
- ⚡ Epilepsy (in over 80% of cases)
- 🧩 Autism features
- 💪 Low muscle tone (hypotonia)
- 🌐 Sensory processing difficulties
👉 Many individuals require lifelong support and care.
🧬 Synonyms and Related Terms
SYNGAP1 disorder may also be referred to as:
- SYNGAP1-related intellectual disability
- Intellectual Developmental Disorder, Autosomal Dominant 5 (MRD5)
- SYNGAP1-related syndrome
🧠 Causes and Genetics
🧪 Genetic Cause
- Most cases are caused by a de novo mutation (new, not inherited from parents)
- Affects one copy of the SYNGAP1 gene
⚖️ Biological Mechanism (Haploinsufficiency)
- The body only produces about 50% of the needed SYNGAP protein
- This protein is essential for regulating synaptic communication in the brain
- Reduced protein levels disrupt brain development and signalling
🧩 Key Features and Symptoms
SYNGAP1 disorder varies between individuals, but common features include:
🧠 Neurological & Developmental
- Global developmental delay
- Delayed speech and language development
- Delayed motor milestones (sitting, walking)
⚡ Epilepsy
- Seizures often begin around age 2
-
Common seizure types include:
- Drop seizures
- Staring spells
- Eyelid myoclonia
👉 Epilepsy is present in over 80% of cases
🧩 Behavioural Features
- Autism spectrum characteristics (around 50% of individuals)
- Sensory processing difficulties
- Repetitive behaviours (e.g. hand-flapping)
- Social communication challenges
💪 Physical Features
Some individuals may also show:
- Low muscle tone (hypotonia)
- Coordination difficulties
- Occasionally distinct facial features (e.g. broad nasal bridge, long nose)
🧪 Diagnosis
SYNGAP1 disorder is diagnosed through:
- 🧬 Genetic testing
- Identification of a heterozygous pathogenic variant in SYNGAP1
- Clinical assessment of developmental and neurological symptoms
🩺 Treatment and Management
👉 There is currently no cure, but support focuses on managing symptoms:
⚡ Medical Management
- Anti-epileptic medication for seizures
- Regular neurological monitoring
🧠 Developmental Support
- Speech and language therapy
- Occupational therapy
- Physiotherapy
- Special educational support
🤝 Long-Term Care
- Individualised care plans
- Family and caregiver support
- Lifelong developmental assistance in many cases
🎯 Key Message
- SYNGAP1 disorder is a genetic brain development condition
- It affects learning, movement, behaviour, and seizure activity
- Symptoms vary but are often significant and lifelong
- Early diagnosis and tailored support improve quality of life
No comments:
Post a Comment